Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
1.
J Med Chem ; 64(8): 4359-4395, 2021 04 22.
Artigo em Inglês | MEDLINE | ID: mdl-33826327

RESUMO

Tuberculosis (TB) is a slow growing, potentially debilitating disease that has plagued humanity for centuries and has claimed numerous lives across the globe. Concerted efforts by researchers have culminated in the development of various strategies to combat this malady. This review aims to raise awareness of the rapidly increasing incidences of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis, highlighting the significant modifications that were introduced in the TB treatment regimen over the past decade. A description of the role of pathogen-host immune mechanisms together with strategies for prevention of the disease is discussed. The struggle to develop novel drug therapies has continued in an effort to reduce the treatment duration, improve patient compliance and outcomes, and circumvent TB resistance mechanisms. Herein, we give an overview of the extensive medicinal chemistry efforts made during the past decade toward the discovery of new chemotypes, which are potentially active against TB-resistant strains.


Assuntos
Antituberculosos/química , Tuberculose Extensivamente Resistente a Medicamentos/patologia , Antituberculosos/farmacologia , Antituberculosos/uso terapêutico , Ciprofloxacina/química , Ciprofloxacina/farmacologia , Ciprofloxacina/uso terapêutico , Progressão da Doença , Portadores de Fármacos/química , Avaliação Pré-Clínica de Medicamentos , Farmacorresistência Bacteriana/genética , Tuberculose Extensivamente Resistente a Medicamentos/tratamento farmacológico , Tuberculose Extensivamente Resistente a Medicamentos/imunologia , Humanos , Testes de Sensibilidade Microbiana , Mycobacterium tuberculosis/efeitos dos fármacos , Estreptomicina/química , Estreptomicina/farmacologia , Estreptomicina/uso terapêutico , Relação Estrutura-Atividade , Tiofenos/química , Tiofenos/farmacologia , Tiofenos/uso terapêutico , Receptores Toll-Like/metabolismo
2.
Drug Chem Toxicol ; 42(2): 220-230, 2019 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-30747009

RESUMO

Chlorpyrifos (CPF) has been considered as one of the most potent organophosphates and is linked to several neurological disorders. On the other hand, Quercetin is a vital plant flavanoid and has been reported to regulate a number of physiological processes in the central nervous system. The present study was conducted to investigate the protective potential of quercetin during chlorpyrifos induced neurotoxicity. Female Wistar rats weighing 150-200 g were divided into four different groups viz: Normal control, CPF treated (13.5 mg/kg.b.wt. every alternate day), Quercetin treated (50 mg/kg.b.wt./day) and combined CPF and quercetin-treated. All the treatments were carried out for a total duration of eight weeks. Chlorpyrifos treatment showed significant alterations in the cognitive behavior and motor activities of rats, which were appreciably improved upon simultaneous supplementation with quercetin. Further, CPF treatment caused a significant inhibition in the enzyme activities of acetylcholinesterase and choline acetyltransferase, but caused an increase in the levels of acetylcholine in the brain. Further, chlorpyrifos exposure significantly elevated the levels of lipid peroxidation and protein carbonyl contents as well as the activities of catalase, superoxide dismutase, which were interestingly found to be decreased following co-treatment with quercetin. In contrast, CPF treatment decreased the activities of glutathione reductase, transferase, as well as levels of reduced and total glutathione in both the cerebrum and cerebellum but co-administration of quercetin, increased these levels. Chlorpyrifos treatment altered the neuro-histoarchitecture, which showed improvement upon quercetin supplementation. Hence, this study suggests that quercetin can be used as a prophylactic intervention to prevent CPF induced neurotoxicity.


Assuntos
Encéfalo/efeitos dos fármacos , Clorpirifos/toxicidade , Fármacos Neuroprotetores/farmacologia , Neurotoxinas/toxicidade , Quercetina/farmacologia , Acetilcolina/análise , Acetilcolinesterase/metabolismo , Animais , Encéfalo/enzimologia , Encéfalo/metabolismo , Química Encefálica/efeitos dos fármacos , Catalase/metabolismo , Clorpirifos/antagonistas & inibidores , Colina O-Acetiltransferase/metabolismo , Feminino , Peroxidação de Lipídeos/efeitos dos fármacos , Aprendizagem em Labirinto/efeitos dos fármacos , Atividade Motora/efeitos dos fármacos , Neurotoxinas/antagonistas & inibidores , Ratos , Ratos Wistar , Superóxido Dismutase/metabolismo
3.
Biol Trace Elem Res ; 179(2): 247-258, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28261760

RESUMO

In the present world, X-rays have been regarded as one of the most efficient tools in medicine, industry and research. On the contrary, extensive human exposure to these rays is responsible for causing detrimental effects on physiological system. The aim of the present study was to investigate the role of zinc (Zn), if any, in mitigating the adverse effects induced by fractionated X-irradiation on rat brain. Female Sprague-Dawley rats weighing 170-200 g were divided into four different groups viz.: (a) normal control, (b) X-irradiated (21Gy), (c) zinc treated (227 mg/L in drinking water) and (d) X-irradiated + zinc treated. The skulls of animals belonging to groups (b) and (d) were exposed to X-rays in 30 fractions. Each fraction delivered a radiation dose of 70 rads, and rats were exposed to two fractions every day for 15 days, consecutively. X-ray treatment resulted in significant alterations in the neurobehavior, neurotransmitter levels and neuro-histoarchitecture of rats, whereas zinc co-treatment with X-rays resulted in significant improvement in these parameters. X-ray exposure also caused a significant increase in the levels of lipid peroxidation as well as activities of catalase and superoxide dismutase, which however were decreased upon simultaneous Zn treatment. On the contrary, X-ray treatment down-regulated the glutathione system, which were found to be up-regulated by zinc co-treatment. Further, protein expressions of p53 and NF-ҚB were found to be significantly elevated after X-irradiation, which were reversed following Zn supplementation. Hence, Zn seems to be an effective agent in mitigating the detrimental effects caused by exposure to X-rays.


Assuntos
Encéfalo/efeitos da radiação , Lesões por Radiação/prevenção & controle , Protetores contra Radiação/farmacologia , Raios X/efeitos adversos , Zinco/farmacologia , Acetilcolinesterase/metabolismo , Animais , Ansiedade/etiologia , Encéfalo/efeitos dos fármacos , Encéfalo/fisiologia , Catalase/metabolismo , Dopamina/metabolismo , Feminino , Glutationa/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Peroxidação de Lipídeos/efeitos da radiação , Locomoção/efeitos dos fármacos , Locomoção/efeitos da radiação , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/fisiologia , Músculo Esquelético/efeitos da radiação , Lesões por Radiação/tratamento farmacológico , Lesões por Radiação/etiologia , Ratos Sprague-Dawley , Serotonina/metabolismo , Superóxido Dismutase/metabolismo
4.
Mol Neurobiol ; 54(1): 406-422, 2017 01.
Artigo em Inglês | MEDLINE | ID: mdl-26742519

RESUMO

Metals are considered as important components of a physiologically active cell, and imbalance in their levels can lead to various diseased conditions. Aluminium (Al) is an environmental neurotoxicant, which is etiologically related to several neurodegenerative disorders like Alzheimer's, whereas zinc (Zn) is an essential trace element that regulates a large number of metabolic processes in the brain. The objective of the present study was to understand whether Zn provides any physiological protection during Al-induced neurodegeneration. Male Sprague Dawley rats weighing 140-160 g received either aluminium chloride (AlCl3) orally (100 mg/kg b.wt./day), zinc sulphate (ZnSO4) in drinking water (227 mg/L) or combined treatment of aluminium and zinc for 8 weeks. Al treatment resulted in a significant decline in the cognitive behaviour of rats, whereas zinc supplementation caused an improvement in various neurobehavior parameters. Further, Al exposure decreased (p ≤ 0.001) the levels of neurotransmitters, acetylcholinesterase activity, but increased (p ≤ 0.001) the levels of L-citrulline as well as activities of nitric oxide and monoamine oxidase in the brain. However, zinc administration to Al-treated animals increased the levels of neurotransmitters and regulated the altered activities of brain markers. Western blot of tau, amyloid precursor protein (APP), glial fibrillary acidic protein (GFAP), ubiquitin, α-synuclein and Hsp 70 were also found to be elevated after Al exposure, which however were reversed following Zn treatment. Al treatment also revealed alterations in neurohistoarchitecture in the form of loss of pyramidal and Purkinje cells, which were improved upon zinc co-administration. Therefore, the present study demonstrates that zinc improves cognitive functions by regulating α-synuclein and APP-mediated molecular pathways during aluminium-induced neurodegeneration.


Assuntos
Alumínio/toxicidade , Disfunção Cognitiva/tratamento farmacológico , Disfunção Cognitiva/patologia , Doenças Neurodegenerativas/tratamento farmacológico , Doenças Neurodegenerativas/patologia , Neurônios/patologia , Zinco/uso terapêutico , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Encéfalo/patologia , Disfunção Cognitiva/induzido quimicamente , Masculino , Doenças Neurodegenerativas/induzido quimicamente , Neurônios/efeitos dos fármacos , Neurônios/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Estresse Oxidativo/fisiologia , Ratos , Ratos Sprague-Dawley , Zinco/farmacologia
5.
J Neurosci Res ; 93(9): 1434-41, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25908409

RESUMO

Aluminium (Al) is one of the most prominent metals in the environment and is responsible for causing several neurological disorders, including Alzheimer's disease. On the other hand, zinc (Zn) is an essential micronutrient that is involved in regulating brain development and function. The present study investigates the protective potential of Zn in the uptake of (14) C-labeled amino acids and glucose and their turnover in rat brain slices during Al intoxication. Male Sprague Dawley rats (140-160 g) were divided into four different groups: normal control, Al treated (100 mg/kg body weight/day via oral gavage), Zn treated (227 mg/liter in drinking water), and Al + Zn treated. Radiorespirometric assay revealed an increase in glucose turnover after Al exposure that was attenuated after Zn treatment. Furthermore, the uptake of (14) C-labeled glucose was increased after Al treatment but was appreciably decreased upon Zn supplementation. In addition, the uptakes of (14) C-lysine, (14) C-leucine, and (14) C-aspartic acid were also found to be elevated following Al exposure but were decreased after Zn treatment. Al treatment also caused alterations in the neurohistoarchitecture of the brain, which were improved after Zn coadministration. Therefore, the present study suggests that Zn provides protection against Al-induced neurotoxicity by regulating glucose and amino acid uptake in rats, indicating that Zn could be a potential candidate for the treatment of various neurodegenerative disorders.


Assuntos
Alumínio/toxicidade , Metabolismo dos Carboidratos/efeitos dos fármacos , Glucose/metabolismo , Doenças Neurodegenerativas/induzido quimicamente , Zinco/farmacologia , Aminoácidos/metabolismo , Análise de Variância , Animais , Isótopos de Carbono/metabolismo , Córtex Cerebral/efeitos dos fármacos , Córtex Cerebral/metabolismo , Modelos Animais de Doenças , Técnicas In Vitro , Masculino , Ratos , Ratos Sprague-Dawley
6.
Biometals ; 28(1): 61-73, 2015 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-25381639

RESUMO

Aluminium (Al), a ubiquitous element in nature is associated with the onset of Alzheimer's disease. On the other hand, zinc (Zn) is an essential trace element that regulates large number of physiological processes in the human body. The present study was conducted to explore the role of zinc, if any, in regulating apoptotic machinery during Al induced neurodegeneration in rat. Male sprague dawley rats weighing 140-160 g were divided into four different groups viz: Normal control, Al treated (100 mg/kg b.wt./day), Zn treated (227 mg/l) and combined Al and Zn treated. All the treatments were carried out for a total duration of 8 weeks. Al treatment resulted in a significant increase in the protein expressions of cytochrome c, Bax, Apaf-1, caspase 9, caspase 3 (p17), caspase 8, caspase 6, caspase 7 but decreased the Bcl-2 in both the cerebrum and cerebellum. However, Zn supplementation to Al treated rats resulted in a reduction in the protein expressions of cytochrome c, Bax, Apaf-1, caspase 9, caspase 3 (p17), caspase 8, caspase 6 and caspase 7 whereas it elevated the Bcl-2 in both the regions. Further, gene expressions of caspase 3 and caspase 9 were also found to be elevated after Al treatment, which however were reduced following Zn co-treatment. The electron-microscopic analysis of brain revealed that Al intoxication resulted in a number of degenerative signs at ultrastructural level, which were appreciably improved upon Zn supplementation. The present study suggests that Zn provides protection against Al induced neurotoxicity by triggering anti-apoptotic machinery.


Assuntos
Alumínio/toxicidade , Proteínas Proto-Oncogênicas c-bcl-2/metabolismo , Zinco/farmacologia , Proteína X Associada a bcl-2/metabolismo , Animais , Apoptose/efeitos dos fármacos , Caspase 3/metabolismo , Caspase 6/metabolismo , Caspase 7/metabolismo , Cerebelo/efeitos dos fármacos , Cerebelo/metabolismo , Cérebro/efeitos dos fármacos , Cérebro/metabolismo , Ativação Enzimática/efeitos dos fármacos , Masculino , Microscopia Eletrônica de Transmissão , Ratos , Ratos Sprague-Dawley , Reação em Cadeia da Polimerase em Tempo Real
7.
Metallomics ; 6(10): 1941-50, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-25141099

RESUMO

Dysregulation of metal homeostasis has been perceived as one of the key factors in the progression of neurodegeneration. Aluminium (Al) has been considered as a major risk factor, which is linked to several neurodegenerative diseases, especially Alzheimer's disease, whereas zinc (Zn) has been reported as a vital dietary element, which regulates a number of physiological processes in central nervous system. The present study was conducted to explore the protective potential of zinc, if any, in ameliorating neurotoxicity induced by aluminium. Male Sprague Dawley rats received either aluminium chloride (AlCl3) orally (100 mg kg(-1) b.wt. per day), zinc sulphate (ZnSO4) at a dose level of 227 mg L(-1) in drinking water or combined treatment of aluminium and zinc for 8 weeks. Aluminium treatment significantly elevated the levels of lipid peroxidation and reactive oxygen species as well as the activities of catalase, superoxide dismutase and glutathione reductase, which however were decreased following Zn co-treatment of Al-treated rats. In contrast, Al treatment decreased the activities of glutathione-S-transferase as well as the levels of reduced glutathione, oxidised glutathione and total glutathione, but co-administration of Zn to Al-treated animals increased these levels. Furthermore, Al treatment caused a significant increase in the levels of Fe and Mn as well as of Al but decreased the Zn and metallothionein levels. In the Zn-supplemented animals, the levels of Al, Fe, Mn were found to be significantly decreased, whereas the levels of metallothionein as well as Zn were increased. Moreover, histopathological alterations such as vacuolization and loss of Purkinje cells were also evident following Al treatment, which showed improvement upon Zn supplementation. Therefore, zinc has the potential to alleviate aluminium-induced neurodegeneration.


Assuntos
Compostos de Alumínio/toxicidade , Encéfalo/efeitos dos fármacos , Cloretos/toxicidade , Fármacos Neuroprotetores/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Sulfato de Zinco/farmacologia , Cloreto de Alumínio , Compostos de Alumínio/administração & dosagem , Animais , Encéfalo/citologia , Encéfalo/metabolismo , Encéfalo/patologia , Catalase/metabolismo , Cloretos/administração & dosagem , Glutationa/metabolismo , Glutationa Redutase/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Metalotioneína/metabolismo , Fármacos Neuroprotetores/administração & dosagem , Ratos Sprague-Dawley , Espécies Reativas de Oxigênio/metabolismo , Superóxido Dismutase/metabolismo , Sulfato de Zinco/administração & dosagem
8.
Mol Neurobiol ; 50(2): 613-25, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24500000

RESUMO

Metals perform important functions in the normal physiological system, and alterations in their levels may lead to a number of diseases. Aluminium (Al) has been implicated as a major risk factor, which is linked to several neurodegenerative diseases including Alzheimer's disease and Parkinson's disease. On the other hand, zinc (Zn) is considered as a neuromodulator and an essential dietary element that regulates a number of biological activities in our body. The aim of the present study was to investigate the effects of Zn supplementation, if any, in ameliorating the changes induced by Al on calcium signalling pathway. Male Sprague Dawley rats weighing 140-160 g were divided into four different groups viz.: normal control, aluminium treated (100 mg/kg b.wt./day via oral gavage), zinc treated (227 mg/l in drinking water) and combined aluminium and zinc treated. All the treatments were carried out for a total duration of 8 weeks. Al treatment decreased the Ca(2+) ATPase activity whereas increased the levels of 3', 5'-cyclic adenosine monophosphate, intracellular calcium and total calcium content in both the cerebrum and cerebellum, which, however, were modulated upon Zn supplementation. Al treatment exhibited a significant elevation in the protein expressions of phospholipase C, inositol triphosphate and protein kinase A but decreased the expression of protein kinase C, which, however, was reversed upon Zn co-treatment. Al treatment also revealed alterations in neurohistoarchitecture in the form of calcium deposits, which were improved upon zinc co-administration. The present study, therefore, suggests that zinc regulates the intracellular calcium signalling pathway during aluminium-induced neurodegeneration.


Assuntos
Alumínio/farmacologia , Sinalização do Cálcio/efeitos dos fármacos , Cálcio/metabolismo , Cerebelo/efeitos dos fármacos , Cérebro/efeitos dos fármacos , Zinco/farmacologia , Animais , Cerebelo/metabolismo , Cérebro/metabolismo , Masculino , Doenças Neurodegenerativas/induzido quimicamente , Estresse Oxidativo/efeitos dos fármacos , Ratos Sprague-Dawley , Zinco/metabolismo
9.
Environ Toxicol ; 29(3): 320-7, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22422511

RESUMO

The study was carried out to assess the role of zinc (Zn) in mitigating the biochemical alterations induced by aluminum (Al) in rat liver. Rats were divided into four groups: normal control, Al treated (AlCl3, 100 mg/kg b.wt./day), Zn treated (ZnSO4, 227 mg/L drinking water), and combined Al + Zn treated. Al and zinc treatments were given for a total duration of 2 months. Al treatment caused a significant increase in the activity of alkaline phosphatase (ALP), but decreased aspartate aminotransferase (AST) and alanine aminotranferase (ALT) activities, which showed the reverse trend following Zn supplementation. Levels of lipid peroxidation (LPx) and activities of catalase and glutathione-S-transferase (GST) were significantly decreased following Al treatment, which, however, were increased significantly in Zn co-treated rats. Further Al exposure showed a significant increase in reduced glutathione (GSH) content as well as activities, of superoxide dismutase (SOD) and glutathione reductase (GR). However, Zn supplementation to Al-treated rats brought down the raised levels of reduced (GSH) and SOD to within normal limits, but caused no effect on GR activity. Furthermore, Al treatment also resulted in alterations in liver histoarchitecture with disruption of hepatic cords and increased vacuolization, which were close to normal following Zn supplementation. The present study reveals that Zn is effective in attenuating the liver damage inflicted by Al toxicity.


Assuntos
Alumínio/toxicidade , Fígado/efeitos dos fármacos , Estresse Oxidativo/efeitos dos fármacos , Zinco/farmacologia , Fosfatase Alcalina/metabolismo , Animais , Antioxidantes/metabolismo , Aspartato Aminotransferases/metabolismo , Catalase/metabolismo , Feminino , Glutationa/metabolismo , Glutationa Peroxidase/metabolismo , Glutationa Redutase/metabolismo , Glutationa Transferase/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Fígado/metabolismo , Fígado/patologia , Ratos , Ratos Sprague-Dawley , Superóxido Dismutase/metabolismo
10.
Cell Mol Neurobiol ; 34(2): 269-76, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24287498

RESUMO

The present study was designed to understand the influence of zinc (Zn) if any, on the biokinetics of (65)Zn in brain as well as whole body and its bio-distribution following aluminium (Al) treatment to rats. Male Sprague-Dawley rats weighing 140-160 g were divided into four different groups viz: normal control, aluminium treated (100 mg/kg b.wt./day via oral gavage), zinc treated (227 mg/L in drinking water) and combined aluminium and zinc treated. All the treatments were carried out for a total duration of 8 weeks. Al treatment showed a significant increase in fast component (Tb1) but revealed a significant decrease in slow component (Tb2) of biological half-life in brain as well as in whole body. However, Zn supplementation to Al-treated rats reversed the trend in both brain and whole body, which indicates a significant decrease in Tb1 component while the Tb2 component was significantly increased. Further, Al treatment showed an increased percent uptake value of (65)Zn in cerebrum, cerebellum, heart, liver and lungs whereas a decrease in uptake was found only in blood. On the other hand, there was a significant decline in (65)Zn activity in nuclear and mitochondrial fractions of brain of Al-treated rats. However, Zn treatment reversed the altered (65)Zn uptake values in different organs as well as in various subcellular fractions. The study demonstrates that Zn shall prove to be effective in regulating the biokinetics of (65)Zn in brain and whole body and its distribution at the tissue and subcellular levels in Al-treated rats.


Assuntos
Alumínio/toxicidade , Encéfalo/metabolismo , Zinco/farmacologia , Zinco/farmacocinética , Animais , Encéfalo/efeitos dos fármacos , Cerebelo/efeitos dos fármacos , Cerebelo/metabolismo , Cerebelo/patologia , Cérebro/efeitos dos fármacos , Cérebro/metabolismo , Cérebro/patologia , Meia-Vida , Masculino , Ratos , Ratos Sprague-Dawley , Frações Subcelulares/efeitos dos fármacos , Frações Subcelulares/metabolismo , Distribuição Tecidual/efeitos dos fármacos
11.
Mol Neurobiol ; 48(1): 1-12, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23420078

RESUMO

Aluminum (Al) has been considered as one of the most abundant elements and comprises nearly 8 % of the Earth's crust. Despite of its immense presence, studies regarding the molecular basis of its interaction with the physiological system are rather sparse. On the other hand, zinc (Zn), an essential micronutrient, has been regarded as the second most important metal for brain functioning. The objective of the present study was to investigate the protective potential of Zn, if any, during Al-induced detrimental effects on DNA, tritiated thymidine uptake as well as expression of stress marker genes and proteins in rat brain. Male Sprague-Dawley rats weighing 140-160 g were divided into four different groups viz.: normal control, Al treated (100 mg/kg b wt/day via oral gavage), Zn treated (227 mg/l in drinking water), and combined Al and Zn treated. All the treatments were carried out for a total duration of 8 weeks. Agarose gel electrophoresis revealed DNA laddering pattern and comets in the rat brain following Al treatment, which however, were attenuated upon Zn treatment. Further, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive cells, number of apoptotic brain cells, and uptake of tritiated thymidine were increased after Al treatment but were decreased upon Zn supplementation. Western blot and mRNA expressions of p53 and nuclear factor κB (NF-κB) were also found to be significantly elevated after Al treatment, which however, were reversed following Zn treatment. Hence, Zn shall prove to be an effective agent in mitigating the detrimental effects caused by Al in the rat brain.


Assuntos
Alumínio/toxicidade , Dano ao DNA , Fármacos Neuroprotetores/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Zinco/farmacologia , Animais , Apoptose/efeitos dos fármacos , Cerebelo/efeitos dos fármacos , Cerebelo/metabolismo , Cérebro/efeitos dos fármacos , Cérebro/metabolismo , Ensaio Cometa , DNA/isolamento & purificação , Fragmentação do DNA/efeitos dos fármacos , Densitometria , Eletroforese em Gel de Ágar , Marcação In Situ das Extremidades Cortadas , Masculino , Microscopia de Fluorescência , NF-kappa B/metabolismo , Ratos , Ratos Sprague-Dawley , Timidina/metabolismo , Trítio/metabolismo , Proteína Supressora de Tumor p53/metabolismo
12.
Food Chem Toxicol ; 55: 18-28, 2013 May.
Artigo em Inglês | MEDLINE | ID: mdl-23313339

RESUMO

The aim of the present study was to investigate the effects of Zinc (Zn) supplementation on lipid profile and fluidity of cerebrum and cerebellum membranes of rats treated with aluminium (Al). Sprague dawley male rats were divided into four different treatment groups viz: Control, aluminium treated, zinc treated and aluminium+zinc treated. Aluminium (AlCl3) was administered orally at a dose of 100mg/kgb.wt./day (dissolved in drinking water). Zinc as zinc sulphate was supplemented to rats at a dose of 227mg/l in drinking water. A significant decrease in the levels of total lipids, glycolipids, phospholipids, cholesterol and gangliosides contents were observed in both the cerebrum and cerebellum following Al exposure, which were found to be significantly increased following Zn supplementation. On the contrary, Al treatment caused a significant increase in the formation of conjugated dienes, which were observed to be reduced on Zn co-treatment. Further, Al treatment significantly elevated the fluorescence polarization, anisotropy and order parameter, which however were normalized upon Zn co-administration. Hence, the present study depicts the potential of Zn in moderating the changes caused by Al on membrane composition and fluidity in rat brain.


Assuntos
Alumínio/efeitos adversos , Membrana Celular/efeitos dos fármacos , Lipídeos/sangue , Zinco/farmacologia , Animais , Masculino , Sistema Nervoso/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley
13.
Neurotox Res ; 22(2): 115-26, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22247011

RESUMO

Curcumin is being widely used both as an herbal drug and a food additive in Asian countries. However, its prophylactic potential in containing certain brain disorders is yet to be fully explored. The present study was conceived with an idea that curcumin may prove to be effective in ameliorating N-methyl N-nitrosourea (MNU)-induced adverse effects in cerebrum and cerebellum of mice. Male laca mice received either intravenous MNU treatment at a dose of 10 mg/kg body weight in sterile double distilled water, curcumin alone 60 mg/kg body weight in drinking water via oral gavage, or combined MNU and curcumin treatment on alternate days for a total duration of 2 months. MNU treatment resulted in significant alteration in neurobehavior, reactive oxygen species, lipid profile and histoarchitecture which showed appreciable signs of improvements upon curcumin supplementation. Therefore, the study concludes that prophylactic treatment with curcumin shall prove to be effective in containing MNU-induced neurotoxicity.


Assuntos
Alquilantes/toxicidade , Encéfalo/patologia , Curcumina/farmacologia , Metilnitrosoureia/toxicidade , Fármacos Neuroprotetores , Acetilcolinesterase/metabolismo , Animais , Ansiedade/induzido quimicamente , Ansiedade/psicologia , Encéfalo/efeitos dos fármacos , Cerebelo/efeitos dos fármacos , Cerebelo/enzimologia , Cerebelo/metabolismo , Glutationa/metabolismo , Glutationa Transferase/metabolismo , Peroxidação de Lipídeos/efeitos dos fármacos , Masculino , Lipídeos de Membrana/metabolismo , Camundongos , Monoaminoxidase/metabolismo , Atividade Motora/efeitos dos fármacos , Neurotransmissores/metabolismo , Espécies Reativas de Oxigênio/metabolismo
14.
J Neurosci Res ; 90(3): 698-705, 2012 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-22108899

RESUMO

Aluminium is considered an environmental neurotoxicant and causes many neurological disorders, whereas zinc is vital for many biological functions. The present study was carried out to investigate the role of Zn, if any, in mitigating the adverse effects inflicted by Al on carbohydrate metabolism in rat brain. Male Sprague-Dawley rats weighing 140-160 g were divided into four different groups: normal control, Al-treated (100 mg/kg b.w./day in drinking water via oral gavage), Zn-treated (227mg/liter in drinking water), and combined Al- and Zn-treated rats. All the treatments were continued for 2 months, and their effects on carbohydrate-metabolizing enzymes were studied. Additionally, expressions of the proteins glycogen synthase kinase-3 (GSK3) and protein phosphatase (PP1), which help in regulating carbohydrate energy metabolism, were also studied. Al treatment resulted in increased activities of the glucose-6-phosphatase (G6P), glucose-6-isomerase (G6I), and lactate dehydrogenase (LDH), whereas the activities of hexokinase and succinate dehydrogenase (SDH) and glycogen content were decreased. Moreover, no significant change was observed in the biochemical parameters upon Zn supplementation alone. However, Zn supplementation to Al-treated rats was able to reduce significantly the Al-induced increased activities of G6P, G6I, and LDH, but it elevated the levels of hexokinase, SDH, and glycogen. Furthermore, Al treatment increased the protein expression of GSK3 and decreased the PP1 expression, which were found to be reversed upon Zn administration. Hence, Zn is effective in regulating theAl-induced alterations in carbohydrate metabolism.


Assuntos
Compostos de Alumínio/farmacologia , Encéfalo/metabolismo , Metabolismo dos Carboidratos/efeitos dos fármacos , Cloretos/farmacologia , Sulfato de Zinco/farmacologia , Cloreto de Alumínio , Compostos de Alumínio/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Cloretos/metabolismo , Glucose-6-Fosfatase/metabolismo , Glicogênio/metabolismo , Hexoquinase/metabolismo , Masculino , Ratos , Ratos Sprague-Dawley , Sulfato de Zinco/metabolismo
15.
Biometals ; 23(2): 197-206, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19936942

RESUMO

The present study was aimed to explore the potential of an antidepressant drug lithium (Li) in reducing aluminium (Al) induced neurotoxicity. To carry out the investigations, Al was administered orally (100 mg AlCl(3)/Kg b wt/day) whereas, Li was administered through diet (1.1 g Li(2)CO(3)/Kg diet, daily) for a total duration of 2 months. Al treatment resulted in a significant increase in the activity of enzyme nitric oxide synthase and the levels of L-citrulline which, however, were decreased appreciably following lithium supplementation. Al treatment also revealed an increase in DNA fragmentation as evidenced by an increase in number of comets. Interestingly, Li supplementation to Al treated rats reduced the damage inflicted on DNA by Al. Ultrastructural studies revealed an increase in chromatin condensation with discontinuity in nuclear membrane in both the cerebrum and cerebellum of Al treated rats which showed improvement following Li supplementation. Alterations in the structure of synapse and mitochondrial swelling were also seen. The present study shows the potential of Li in containing the damage inflicted by Al on rat brain.


Assuntos
Alumínio/toxicidade , Antidepressivos/farmacologia , Encéfalo/efeitos dos fármacos , Lítio/farmacologia , Animais , Antidepressivos/administração & dosagem , Encéfalo/metabolismo , Encéfalo/ultraestrutura , Citrulina/metabolismo , Ensaio Cometa , Dano ao DNA , Suplementos Nutricionais , Humanos , Lítio/administração & dosagem , Óxido Nítrico Sintase/metabolismo , Distribuição Aleatória , Ratos , Ratos Sprague-Dawley
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA